Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Stocks Undercut as Little Progress is seen in U.S. Debt Ceiling Talks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.63%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IU ) (QQQ ) closed up +0.09%. Stock indexes Tuesday settled mixed, with the Dow Jones...

Barchart

Stocks Mixed as Debt Ceiling Talks Resume

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.16%. U.S. stocks this morning are mixed, with the Dow...

Barchart

The Vaccine Problem

To better weather future pandemics, the way countries procure vaccines needs to change radically

The Walrus

From analysis to the latest developments in health,
read the most diverse news in one place.

Obesity speeds up loss of immunity from COVID vaccines – new research

COVID vaccines are very effective, but for some groups they don’t generate as strong an immune response. These groups include older adults and people with weakened immune systems, for example due to cancer or other medical conditions. They tend to already be at heightened risk from COVID.

The Conversation

FDA's approval of the world's first vaccine against RSV will offer a new tool in an old fight – 4 questions answered

The U.S. Food and Drug Administration approved the world’s first vaccine to prevent the respiratory infection RSV, short for respiratory syncytial virus, on May 3, 2023. The new shot represents six decades of starts and stops in the hunt for a vaccine to curb one of the most common winter…

The Conversation

AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

Businessweek

Two of the best drugs for stopping smoking aren't available in UK

'Process of making both varenicline and cytisine available feels excruciatingly slow'

Wales Online

Read news from The Economist, FT, and more,
with one subscription

FDA approves first vaccine for respiratory syncytial virus

The FDA has approved the first vaccine for respiratory syncytial virus (RSV).

The Hindu

The best drugs for stopping smoking that you probably can’t have – new review

When so much time and effort goes into developing the best medical treatments, we expect them to be available when we need them. The same goes for addiction treatments, so it’s worrying that two of the most effective drugs for quitting smoking aren’t available in the UK.

The Conversation

FDA approves 1st RSV vaccine for older adults

After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer — especially after a virus surge that strained hospitals last fall.

Chicago Sun-Times

FDA approves United States' first-ever RSV vaccine

GSK's RSV vaccine is approved for people aged 60 and older.

Axios

US approves first vaccine for RSV after decades of attempts

The US has approved the first vaccine for RSV, shots to protect older adults

The Independent UK

Attorney General Ken Paxton to investigate COVID-19 vaccine makers

Long an opponent of vaccine and mask mandates, the Republican said pharmaceutical companies may have misrepresented data. Pfizer strongly disagrees.

The Texas Tribune

Pfizer, BioNTech Propose EU Pays Half for Each Cancelled COVID Dose

Pfizer Inc and BioNTech's new proposal to the European Union, amid a glut of COVID-19 shots, includes a provision for member states to pay half price, or about 10 euros ($11), for each of about 70 million cancelled doses, the Financial Times reported on Sunday. The revised contract would allow…

Asharq Al-Awsat

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

People urged to start wearing masks and testing thanks to new Covid strain

Experts say it is up to individuals to help stop the spread of the disease

The Guardian - UK

UK and Europe are falling behind US and China in biotech, says AstraZeneca boss

Pascal Soriot says decline in startups across Europe differs markedly from ‘explosion’ of firms and clinical trials in China

WEKU

What lessons have we learned from the COVID pandemic?

The nonpartisan Covid Crisis Group has released its investigative report, titled "Lessons from the Covid War: An Investigative Report." This is what it found.

The Guardian - UK

AstraZeneca overtakes Pfizer as crunch week for UK pharma looms

Driven by a revamped drug portfolio, AstraZeneca is expected to report revenues of $10.7bn in its latest quarterly results

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

Los Angeles Times

CDC has approved spring COVID booster for some. Do you need it?

Another COVID-19 booster shot is on the way as federal health officials look to further augment protection for those at greater risk of developing severe disease.

The Independent UK

Extra spring COVID booster cleared for certain Americans

Certain Americans at high risk from COVID-19 can get an extra vaccine booster this spring

Evening Standard

Autumn Covid booster 2023: Who is eligible for another jab?

If invited, you will receive a booster dose of a Covid-19 vaccine made by Pfizer, Moderna, or Sanofi

The Week

Sanofi: the new protein-based Covid vaccine to be used in the UK

The University of Edinburgh’s Neil Mabbott on the vaccine technology being used for Covid booster jabs from this month.

Wales Online

5million people called on to get another Covid jab from today

Eligible people include those aged 75 and over, and anyone aged five and over who has a weakened immune system

The Independent UK

Millions eligible for Covid jab as spring booster campaign begins

Around five million people in total are eligible for a booster until the end of June.

1 … 24 25 26 27

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.